Retatrutide in type 2 diabetes mellitus and obesity: an overview.

This narrative overview is centered on retatrutide and consolidates trial findings across diabetes, obesity, and fatty liver outcomes. It reports strong associations with glycemic, weight, and hepatic fat improvements while flagging dose-dependent gastrointestinal effects. As a narrative review it summarizes rather than adds primary evidence.